BioWorld

Sep. 10, 2009

Vivus Soars Over Obesity Finish Line, Jumps into Partner Race

Vivus Inc. wowed analysts and investors on Wednesday with better-than-expected data from its final two Phase III trials of obesity drug Qnexa (phentermine/topiramate CR). (BioWorld Today) Read More

Health Care Tax on Biotechs Drawing Concern from BIO

In Separate Studies, Two New Genes Tied to Hearing Loss

Targeted Genetics Gets $7M Lifeline in Genzyme Deal

CellCyte, Ex-Officers Charged with Misleading Shareholders

Clinic Roundup

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...

FENS 2026: Next-gen biologics take on brain disease

BioWorld

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...

NRF2 activators reported in Vailima Peninsula patent

BioWorld Science

Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...